HEPATITIS B AND HEPATITIS C VIRUS AMONG BLOOD DONORS
|
|
|
- Sylvia Lester
- 6 years ago
- Views:
Transcription
1 HEPATITIS B AND HEPATITIS C VIRUS AMONG BLOOD DONORS VIRAL HEPATITIS PREVENTION BOARD MEETING LISBON, PORTUGAL, November 2010 Gabriel de Olim Presidente do Conselho Directivo do Instituto Português do Sangue, I.P.
2 SUMMARY I. THE PORTUGUESE BLOOD SUPPLY SYSTEM II. DONORS ELEGIBILITY CRITERIA III.HEPATITIS B VIRUS IV.HEPATITIS C VIRUS V. CONCLUSION
3 SUMMARY I. THE PORTUGUESE BLOOD SUPPLY SYSTEM II. DONORS SELECTION CRITERIA III.HEPATITIS B VIRUS IV.HEPATITIS C VIRUS V. CONCLUSIONS
4 BLOOD SERVICES IN PORTUGAL Year 2009 Regional Blood Centre (IPS, I.P.) Public Hospital Blood Service
5 PUBLIC HOSPITALS AND BLOOD SUPPLY Year 2009 Hospital supplied by Oporto Regional B.C. (25) Hospital supplied by Coimbra Regional B.C. (16) Hospital supplied by Lisbon Regional B.C. (13) Hospital Blood Service (22)
6 BLOOD DONATIONS IN PORTUGAL (TREND) Blood Units Donated IPS HOSPITAIS Total
7 BLOOD DONATIONS IN PORTUGAL Year Blood donations Portuguese Blood Institute Hospitals , , , , , ,167
8 FIRST-TIME BLOOD DONORS (National Data) Year First-time donors Portuguese Blood Institute Hospitals ,052 31,776 12,276
9 SUMMARY I. THE PORTUGUESE BLOOD SUPPLY SYSTEM II. DONORS ELEGIBILITY CRITERIA III.HEPATITIS B VIRUS IV.HEPATITIS C VIRUS V. CONCLUSIONS
10 BLOOD DONORS ELEGIBILITY CRITERIA Age - 18; 65 Weight - 50 Kg Eligibility screening questionnaire - filled in privacy. Medical examination - clinically and mentally fitted.
11 DEFERRALS (Portuguese Blood Institute) 35,0% 30,0% 25,0% 20,0% 15,0% 10,0% 5,0% 0,0% ANO
12 TEMPORARY DEFERRALS (Portuguese Blood Institute) Recent history of infectious or parasitic disease 4,856 (6.0%) Recent history of flu 4,567 (5.7%) New sexual partner 4,424 (5.5%) Major surgery in the last 6 months 3,386 (4.2%) GI endoscopy in the last 4 months 2,173 (2.7%) Dentistry in the last 7 days 1,476 (1.8%) Medical decision 14,198 (17.6%)
13 SCREENING LABORATORY TESTS HBsAg HBc antibody HCV antibody HIV ½ antibody HTLV I/II antibody Treponema pallidum antibody HBV / HCV / HIV - NAT ALT
14 SUMMARY I. THE PORTUGUESE BLOOD SUPPLY SYSTEM II. DONORS ELEGIBILITY CRITERIA III.HEPATITIS B VIRUS IV.HEPATITIS C VIRUS V. CONCLUSIONS
15 HEPATITIS B VIRUS Instituto Português do Sangue, I.P.
16 Hepatitis B prevalence in first-time blood donors: HBsAg Source: - ECDC Technical Report. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies
17 SCREENING AND CONTROL TESTS HBsAg - ABBOT; BIORAD Prisma HbsAg, Architect HBSAg, Monolis HBsAg Ultra NAT - ROCHE; CHIRON Cobas Taqscreen MPX test, Proclix Utrio Assay CONTROL - Acrometrix, Pelispy Pro HBV Positive EQC
18 YEAR 2009 HBV Among 44,052 First-time Blood Donors National Data ELISA (+)/NAT (-) HOSPITALS PORTUGUESE BLOOD INSTITUTE Total ELISA (+)/NAT (+) ELISA (-)/NAT (+) Prevalence (%)
19 Hepatitis B Virus : HBsAg (+) or NAT (+) PREVALENCE RATES (%) Portuguese Blood Institute Year All donors First-time donors Repeat donors 2008 (0.03) 1:3,206 (0.18) 1:542 (0.0015) 1:36, (0.03) 1:3,222 (0.23) 1:412 (0.0013) 1:72, (9 months) (0.02) 1:4,300 (0.14) 1:701 (0.0019) 1:52,289
20 YEAR 2010: January- September HBV Among First-time Blood Donors Portuguese Blood Institute ELISA (+)/NAT (-) ELISA (+)/NAT (+) ELISA (-)/NAT (+) COIMBRA RBC LISBON RBC OPORTO RBC
21 YEAR 2010: January-September Lisbon Regional Blood Centre Instituto Português do Sangue, I.P. HBV Among First-time Blood Donors BY AGE GROUP Age Total Male Female Prev.(%) male Prev.(%) female
22 YEAR 2010: January-September Lisbon Regional Blood Centre Instituto Português do Sangue, I.P. HBV Among First-time Blood Donors BY COUNTRY Age Total Gender m/f m/f m/f m/f m/f m/f Portugal 1*/ 1/1 2/1 *Guinea- Bissau 1/1 2/ 3/1 S.Tomé e Príncipe /1 0/1 Angola 2/ 1/ 3/0 Cabo Verde 1/ 1/0 Mauritania 1/ 1/0 Ukraine /1 1/ 1/1 Moldova /1 0/1
23 SUMMARY I. THE PORTUGUESE BLOOD SUPPLY SYSTEM II. DONORS ELEGIBILITY CRITERIA III.HEPATITIS B VIRUS IV.HEPATITIS C VIRUS V. CONCLUSIONS
24 HEPATITIS C VIRUS Instituto Português do Sangue, I.P.
25 Hepatitis C prevalence in first-time blood donors: anti-hcv Source: - ECDC Technical Report. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies
26 SCREENING AND CONTROL TESTS Anti-HCV - ABBOT; ORTHO Prisma HCV, Architect Anti-HCV, Ortho HCV 3.0 ELISA NAT - ROCHE; CHIRON Cobas Taqscreen MPX test, Proclix Utrio Assay CONTROL - Acrometrix, Pelispy Pro HCV Positive EQC
27 YEAR 2009 HCV Among 44,052 First-time Blood Donors National Data ELISA (+)/NAT (-) HOSPITALS PORTUGUESE BLOOD INSTITUTE Total ELISA (+)/NAT (+) ELISA (-)/NAT (+) Prevalence (%)
28 Hepatitis C Virus : Serology or NAT (+) PREVALENCE RATES (%) Portuguese Blood Institute Year All donors First-time donors Repeat donors 2008 (0.02) 1:4,949 (0.11) 1:857 (0.0015) 1:63, (0.02) 1:4,962 (0.14) 1:690 (0.0018) 1:54, (9 months) (0.02) 1:5,136 (0.12) 1:849 (0.0019) 1:52,289
29 YEAR 2010: January-September HCV Among First-time Blood Donors Portuguese Blood Institute ELISA (+)/NAT (-) ELISA (+)/NAT (+) ELISA (-)/NAT (+) COIMBRA RBC LISBON RBC OPORTO RBC
30 YEAR 2010 : January-September Lisbon Regional Blood Centre Instituto Português do Sangue, I.P. PREVALENCES OF HCV AMONG FIRST-TIME BLOOD DONORS BY AGE GROUP Age Total Male Female Prev.(%) male Prev.(%) female
31 YEAR 2010 : January-September Lisbon Regional Blood Centre Instituto Português do Sangue, I.P. HCV AMONG 1st TIME BLOOD DONORS BY COUNTRY OF ORIGIN Age Total Gender m/f m/f m/f m/f m/f m/f Portugal /1 3/1 4/1 2/ 9/3 Brazil 1/ 1/0 East Timor 1/ 1/0 Angola 1/ 1/0 Mozambique 1/ /1 1/1 Ukraine 1/1 1/1
32 SUMMARY I. THE PORTUGUESE BLOOD SUPPLY SYSTEM II. DONORS ELEGIBILITY CRITERIA III.HEPATITIS B VIRUS IV.HEPATITIS C VIRUS V. CONCLUSION
33 CONCLUSION HBV and HCV Prevalence Rates (%) Portuguese Blood Institute Year First-time blood donations HBV HCV Prevalences (%) HBV HCV , , (9 months) 28,
34 Hepatitis B prevalence in first-time blood donors: HBsAg < 0.5 < 0.22 Source: - ECDC Technical Report. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies
35 Hepatitis C prevalence in first-time blood donors: anti-hcv < 0.5 < 0.28 Source: - ECDC Technical Report. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies
36 THANK YOU! OBRIGADO!
National Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands. TransMed conference Bhopal 18 November 2016
Dr. Anton van Weert National Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands TransMed conference Bhopal 18 Introduction Thank you! Anton van Weert, PhD, MBA Manager
NAT Screening of Blood Donations in NBC, TRCS
IPFA/PEI, Italy NAT Screening of Blood Donations in NBC, TRCS 2000-2001 Clinical evaluation using COBAS AmpliiScreen HIV & HCV assays, (MP24) window period rate - 1 : 108,768 for HIV-1 and HCV 2002 Routine
Impact of multi-dye multiplex technology on testing algorithm
Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT
Non-reproductive tissues and cells
Ministry of Health: Institute for Transplantation and Biomedicine / Colour key VIRAL HIV 1 and HIV 2 Hepatitis B Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding More
Non-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding More stringent - recommended Not legy binding and not recommended Tested pathogen Donor test/ technique
Non-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legally binding More stringent - recommended Not legally binding and not recommended Non-reproductive tissues and cells
risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)
Prevention and ResidualR risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Syria Laperche L (Centre National de référence r rence pour les hépatites h B et C en Transfusion)
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legally binding on national level More stringent testing - recommended on national level Not legally binding
Viral Hepatitis in Blood Donors
Viral Hepatitis in Blood Donors VHPB country meeting Prof Asc.Vjollca Durro Microbiology Service Medicine Faculty, Medical University Tirana, 27-28 OCTOBER 2016 1 Transfusion-transmitted viral infections
HEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS. Joana Bikulčienė Director of National blood center
HEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS Joana Bikulčienė Director of National blood center j.bikulciene@kraujodonoryste.lt Organizational structure of Lithuanian blood service 1 specialized
Confirmatory Testing Algorithm. Routine Donor Testing Algorithm
Confirmatory Testing Algorithm Blood Confirmatory ABO/Rh Beckman Coulter PK-ABO/Rh Immucor NEO ABO/Rh Immucor NEO ABO/Rh Immucor Manual ABO/Rh Typing Immucor Manual ABO/Rh Typing Discrepancy Resolution
Non-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legy binding on national level More stringent testing - recomd on national level Not legy binding and not recomd
Donor Screening in The Region. Vincini GA NRL, Melbourne, Australia
Donor Screening in The Region Vincini GA NRL, Melbourne, Australia NRL Established in 1985 Not-for-profit organisation that exists to support laboratories that perform testing for the diagnosis and management
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding on national level More stringent - recommended on national level Not legy binding and not recommended on
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legally binding on national level More stringent testing - recommended on national level Not legally binding
Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors
Journal of the Egyptian Society of Haematology & Research, Vol. 7, No. 2, September: 1-5, 2011 Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors HISHAM
Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012
Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012 SOGAT XXIV Ljubljana, 8-9 May 2013 2012 ISS EQAs for NAT ISS EQA Tri-NAT (HCV,
The Technical Aspects of Pathogen Testing in Canada. Nancy Angus Canadian Blood Services Director, Testing
PERMISSON TO USE: Please note that, by making their presentations available on-line, primary authors have agreed to share their presentations. However, should you want to use some of the data or slides
Structure and duties of Blood service
NATIONAL CENTER FOR TRANSFUSION MEDICINE Prevalence of infectious diseases among Mongolian blood donors Namjil Erdenebayar General director of The National Center for Transfusion Medicine, Mongolia NCTM,
Non-reproductive tissues and cells
Colour key Tested pathogen VIRAL Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legy binding on national level More stringent testing - recommended on national level Not
Anticipating (re)emerging infections to ensure blood safety
Anticipating (re)emerging infections to ensure blood safety Pierre Tiberghien Etablissement Français du Sang, St-Denis and Université de Franche-Comté, Besançon, France IPFA/PEI 23rd International Workshop
Evaluation of run controls for cobas 6800 MPX and HEV assay
Evaluation of run controls for cobas 6800 MPX and HEV assay Marco Koppelman Head of Nucleic Acid testing (NAT) laboratory, National Screening laboratory of Sanquin (NSS) in the Netherlands Satellite Meeting
The Counselling of Blood Donors Identified as HIV Reactive. A Review as from January 2007 until June 2011
The Counselling of Blood Donors Identified as HIV Reactive A Review as from January 2007 until June 2011 The Blood Transfusion Service of Namibia Dr. Regine Redecker Mr. Tinus Matyayi 2 3 Background -TTI
Non-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding More stringent - recommended Not legy binding and not recommended Non-reproductive tissues and cells VIRAL
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC and its technical Directives (particularly 2006/17/EC) More stringent -legally binding, applies for all donations and all donor profiles
Lookback studies to assess viral risks The French experience
Lookback studies to assess viral risks The French experience 2000-2012 S Laperche 1, MF Leconte des Floris 2, J Pillonel 3, L Hauser 2, C Lefort 2, JY Py 2, I Hervé 2, R Djoudi 2 For the French haemovigilance
Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company
Customer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands
PRODUCT CATALOGUE Customer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands Communication +31 72 202 07 30 +31 72 202 07 31 sales@bioqcontrol.com
Customer Service and Ordering Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands
PRODUCT CATALOGUE Customer Service and Ordering Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands Communication +31 72 202 07 30 +31 72 202 07 31 info@bioqcontrol.com www.bioqcontrol.com
The Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
NAT / BLOOD SCREENING - PRODUCT RANGE
NAT / BLOOD SCREENING - PRODUCT RANGE QC Sample Name Analytes Assay / Instrument Page QConnect TriScreen Roche cobas TaqScreen MPX Test, v 2.0 (s201) Roche cobas MPX Test (6800/8800) QConnect Grifols Ultrio
Transfusion transmitted infections in National Haemovigilance Systems: the Greek experience
Transfusion transmitted infections in National Haemovigilance Systems: the Greek experience Global blood product safety 10 April 2019, Rome, Italy Constantina Politis National Coordinating Haemovigilance
13 th International Workshop on HIV & Hepatitis Co-infection June 2017 Lisbon, Portugal
13 th International Workshop on HIV & Hepatitis Co-infection 21-23 June 2017 Lisbon, Portugal Outbreak of acute hepatitis A in men who have sex with men in 2017 - Experience with 26 patients Serviço de
Emerging Pathogens that Impact the Canadian Blood Supply Alberta Vein to Vein Conference March 18-19, 2016
Emerging Pathogens that Impact the Canadian Blood Supply Alberta Vein to Vein Conference March 18-19, 2016 Dr. Margaret Fearon Medical Director, Medical Microbiology, Canadian Blood Services March 18,
Role and missions of a National Reference center for blood borne agents: the French example
Role and missions of a National Reference center for blood borne agents: the French example Virginie Sauvage, PhD Département des Agents Transmissibles par le Sang, Centre National de Référence pour les
Surveillance Report 2014
Surveillance Report 2014 Executive summary We are pleased to present the third report for our stakeholders describing infectious disease surveillance. High quality and timely surveillance is key to the
QSEAL Recovered Plasma Specification
QSEAL Recovered Plasma Specification Background The is part of a series of standards that comprise the Plasma Protein Therapeutics Association (PPTA) QSEAL Standards Program. PPTA's Voluntary Standards
The testing of Donated Blood and Components at NHSBT
The testing of Donated Blood and Components at NHSBT NHSBT is responsible for collecting all donated blood and platelets in England, then processing into components before issuing to client hospitals.
Title: Reactivation of a Hepatitis B without core antibody: a case report.
JCM Accepted Manuscript Posted Online 28 January 2015 J. Clin. Microbiol. doi:10.1128/jcm.03546-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 1 Title: Reactivation of a Hepatitis
UvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication
UvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication Citation for published version (APA): Lieshout-Krikke, R. W. (2016). Residual
Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey
Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey This questionnaire consists of three sections: A. Collection and
2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies
2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1
Viral Hepatitis Burden and Policy Directions in the European Region of WHO
Viral Hepatitis Burden and Policy Directions in the European Region of WHO Dr Nedret Emiroglu WHO Regional Office for Europe Brussels 14-15 October 2010 Global Burden of Chronic Viral Hepatitis 2.7% all
QUALITY CONTROL Infectious Disease
QUALITY CONTROL Infectious Disease 1 Infectious Disease Quality Control The human based material used in the production of our Quality Controls is sourced from the Taiwan Blood Services Foundation (TBSF).
EC CERTIFICATE. National Institute for Biological Standards and Control (NIBSC) Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG UK
National Institute for Biological Standards and Control (NIBSC) EC Certificate - Full Quality Assurance System Approval Certificate Annex IV (excluding sections 4 and 6) of Council Directive 98/79/EC on
Public Health, Infections and Transplantation
Public Health, Infections and Transplantation Dr Kerry Chant Chief Health Officer & Deputy Director General Population and Public Health NSW Ministry of Health May2014 Public Health Infection and Transplantation
Khalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia
1 Regional Lab, Makkah. Saudi Arabia stract: Clinical specificity and genotype/subtype detection of viruses using the Cobas TaqScreen MPX system V 2.0, which is a nucleic acid test (NAT) that uses multiples
Implementation: To be determined by each Service. Change Notification UK National Blood Services No
Date of publication: 30 th October 2017 Implementation: To be determined by each Service Change Notification UK National Blood Services No. 33-2017 This change applies to the Whole Blood and Components
Answering your daily challenges. in the ELISA technology I N FECTI OUS DISEASES. bioelisa
Answering your daily challenges in the ELISA technology I N FECTI OUS DISEASES bioelisa RETROVIRUS HIV is the cause of the most important global pandemic. Due to the lack of vaccination, early diagnosis
Guidance for Industry
Guidance for Industry Advisement for the Use of Gen-Probe Procleix Ultrio Plus Assay for NAT Testing on Cadaveric Donors Release Date: 08/03/14 American Medical Education and Research Association 4757
Plasma for fractionation: South African Plasma Requirements
Plasma for fractionation: South African Plasma Requirements Dr Jeh-han Omarjee Head: Microbiological Sciences NBI is a "not for profit" company committed to providing safe, cost effective, quality medicinal
Epidemiology of blood-borne Infections in Vietnam
IPFA 4 th Asia Workshop on Plasma Quality and Supply Epidemiology of blood-borne Infections in Vietnam Nguyen Thị Lan Anh MD, PhD Center for Bio-Medical Rsearch Screening donated blood for infections:
Surveillance Report 2015
Surveillance Report 2015 Executive summary We are pleased to present the fourth report for our stakeholders describing infectious disease surveillance. High quality and timely surveillance is key to the
Screening donors and donations for transfusion transmissible infectious agents. Alan Kitchen
Screening donors and donations for transfusion transmissible infectious agents Alan Kitchen Aim Not to teach you microbiology To provide and awareness of the big picture To provide an understanding of
BLOOD SAFETY STATUS IN INDONESIA. Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine
BLOOD SAFETY STATUS IN INDONESIA Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine OUTLINE Background Blood services in Indonesia Regulation related to blood safety in Indonesia
Viral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a
Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes
Bible Class: Hepatitis B Virus Infection
Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:
seroprevalence of infectious markers & their trends in blood donors in a hospital based blood bank in north india
Indian J Med Res 142, September 2015, pp 317-322 DOI:1103/0971-5916.166598 seroprevalence of infectious markers & their trends in blood donors in a hospital based blood bank in north india R.N. Makroo,
Inspections, Compliance, Enforcement, and Criminal Investigations. Central Texas Regional Blood & Tissue Center 07-Nov-03
1 of 7 6/10/2009 2:20 PM Inspections, Compliance, Enforcement, and Criminal Investigations Department of Health and Human Services Public Health Service Food and Drug Administration Dallas District 4040
Blood Screening Assays. CTS lab locations where assays are performed are indicated by alpha codes D, P, and T.
Blood Screening Assays CTS lab locations where assays are performed are indicated by alpha codes D, P, and T. D= performed in Dallas lab FEI: 3002580251 P= performed in Phoenix lab FEI: 3000204058 T= performed
THE PORTUGUESE COMMUNITY SCREENING NETWORK
THE PORTUGUESE COMMUNITY SCREENING NETWORK COBATEST Annual Network Meeting 14 May 2018 Presented by: Name goes here Paula Meireles, on behalf of the Community Screening Network EPIUnit ISPUP FUNDING (from
Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/
www.pei.de Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/09.2126 S. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany SoGAT XXII 14 th -15 th April 2011, Rome, Italy Presented at:
Surveillance Report 2016
Surveillance Report 2016 Executive summary We are pleased to present the fifth report for our stakeholders describing infectious disease surveillance. High quality and timely surveillance is key to the
Maximizing Cornea and Tissue Donation through Specimen Quality
Maximizing Cornea and Tissue Donation through Specimen Quality Robert W. Bresler, Sydney D. Gastreich, Elias G. Koulouriotis, Linda S. Martin, Susan Diane Brockmeier, Chak-Sum Ho, PhD Abstract Purpose:
Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI
Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI NAT for cellular blood components in Germany Definition of minimal NAT sensitivity limit (ID)
The Blood Donor: Demographics, Donor Selection and Tests on Donor Blood. Liz Caffrey, Patricia Hewitt and John Barbara
CHAPTER 1 The Blood Donor: Demographics, Donor Selection and Tests on Donor Blood Liz Caffrey, Patricia Hewitt and John Barbara 0.3 OVERVIEW Total 0.254 0.247 A safe and sufficient blood supply depends
Since 1973 all blood donations in the Netherlands
ORIGINAL RESEARCH Rare transmission of hepatitis B virus by Dutch donors with occult infection Ryanne W. Lieshout-Krikke, 1 Marian G.J. van Kraaij, 2 Fikreta Danovic, 2 and Hans L. Zaaijer 1 BACKGROUND:
Epidemiology of different hepatides (B & C) in Lithuania
Epidemiology of different hepatides (B & C) in Lithuania IRMA Čaplinskienė SAULIUS Čaplinskas Head of HIV/AIDS/STI and Hepatitis Surveillance, Centre for Communicable Diseases and AIDS; National ECDC contact
Hepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
[Submitted Electronically]
![[Submitted Electronically]](/thumbs/82/85246007.jpg "[Submitted Electronically]")
[Submitted Electronically] Dr. Matthew J. Kuehnert, Director Office of Blood, Organ, and Other Tissue Safety Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious
SEROLOGICAL STATUS OF HEPATITIS B VIRUS INFECTION AMONG MONKS AND NOVICES AT BUDDHIST MONASTERIES IN THREE TOWNSHIPS, YANGON
SEROLOGICAL STATUS OF HEPATITIS B VIRUS INFECTION AMONG MONKS AND NOVICES AT BUDDHIST MONASTERIES IN THREE TOWNSHIPS, YANGON Moe Pwint 1, Aye Marlar Win 1, Wah Win Htike 1, Khine Khine Su 2, Wai Wai Min
Non-competitive Internal Control Concept for PCR-based Qualitative Assays
Christian O. Simon Roche Molecular Diagnostics Rotkreuz, CH Non-competitive Internal Control Concept for PCR-based Qualitative Assays 23 rd SoGAT Meeting, 16 th 17 th April, 2012, Vilnius, Lithuania Design
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of Accreditation 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK National Infection Service, Public Health England Colindale 61 Colindale Avenue London NW9 5EQ Contact: Dr Sanjiv
CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD
CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD AAJ van Drimmelen, E.R. Bax and W.G.V. Quint, BioQControl (BQC), Delft Diagnostic Laboratories
Infectious Disease Considerations in Organ Donation. Nikole A Neidlinger MD FACS Chief Medical Officer
Infectious Disease Considerations in Organ Donation Nikole A Neidlinger MD FACS Chief Medical Officer Screening Donors and Infectious Disease considerations: Deceased Donor Screening Donors at increased
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets
Overview of Blood Transfusion System of Iran:
Report Article Overview of Blood Transfusion System of Iran: 2002-2011 AM Cheraghali High Institute for Research and Education on Transfusion Medicine, Iran Blood Transfusion Organization and University
Infectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance
Infectious Disease Testing ULTRA Product Line Safety is not a Matter of Chance ULTRA Product Line The best answer for HBV, HCV and HIV screening: a global automated solution for safe results. Monolisa
Directed Semen Donor Eligibility Requirements
Directed Semen Donor Eligibility Requirements Directed (known) reproductive donors using the University Andrology Sperm Banking Program must follow FDA requirements to prevent the transmission of relevant
TRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION:
I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION: A. TRANSFUSION RELATED FATALITY: FDA and MEDIC must be notified immediately, and subsequently in writing, when a possible transfusion related
HUNGARIAN NATIONAL BLOOD TRANSFUSION SERVICE. Dr. Klara Baroti-Tóth, PhD IPFA/PEI 19 th International Workshop Budapest, May, 2012.
HUNGARIAN NATIONAL BLOOD TRANSFUSION SERVICE Dr. Klara Baroti-Tóth, PhD IPFA/PEI 19 th International Workshop Budapest, 23-24 May, 212. BLOOD DONATION G I V I N G I S G O O D ORGAN COORDINATION OFFICE
Epidemiology of Hepatitis C Iran
Seyed Moayed Alavian M.D. Professor of Gastro & Hepatology Editor-in-chief of Glob Hepat Comm Editor-in-chief of Hepatitis Monthly E mail: editor@hepatmon.com Epidemiology of Hepatitis C Iran Epidemiology
The Human Cathelicidin LL37 Peptide has High Plasma Levels in B and C Hepatitis Related to Viral Activity but not to 25-Hydroxyvitamin D Plasma Level
The Human Cathelicidin LL37 Peptide has High Plasma Levels in B and C Hepatitis Related to Viral Activity but not to 25-Hydroxyvitamin D Plasma Level SIMONA ALEXANDRA IACOB 1, EUGENIA PANAITESCU 2, DIANA
Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.
Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Cinzia Keechilot, Veena Shenoy 1,V Anil kumar 2,Lalita Biswas 3. MBBS student * Transfusion
Update on Transfusion- Transmitted Infectious Diseases
Update on Transfusion- Transmitted Infectious Diseases Scott Koepsell MD PhD Associate Professor University of Nebraska Medical Center I have no conflicts of interest to disclose. Global changes and the
BLOOD DONATION OR BLOOD DONOR DEFERRAL BASED ON DATA ON NONCONFORMITIES DETECTED IN POST-SELECTION PERIOD (DURING AND AFTER BLOOD COLLECTION)
BLOOD DONATION OR BLOOD DONOR DEFERRAL BASED ON DATA ON NONCONFORMITIES DETECTED IN POST-SELECTION PERIOD (DURING AND AFTER BLOOD COLLECTION) Tomislav Vuk Croatian Institute of Transfusion Medicine Zagreb
Increased Risk Donors. November 1, 2018 BC Kidney Days. Jagbir Gill MD MPH Associate Professor of Medicine UBC
Increased Risk Donors November 1, 2018 BC Kidney Days Jagbir Gill MD MPH Associate Professor of Medicine UBC Median dialysis exposure prior to DDKT Case scenarios Which donors should we accept kidneys
The Hepatitis B-e antigen-positive
The Hepatitis B-e antigen-positive Dental Student Developing an Equitable Policy Hepatitis B Virus Serology 1 HBsAg A protein on the surface of HBV; it can be detected in high levels in serum during acute
Screening Volunteer Blood Donations for Transmissible Infectious Diseases
Screening Volunteer Blood Donations for Transmissible Infectious Diseases Joan D. McAuley, MT(ASCP), CHS(ABHI), Gene F. Robertson, PhD (Blood Systems Laboratories, Tempe, AZ) DOI: 10.1309/YKW4JAF2RGFE3V0K
Dr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1
Dr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1 No disclosures. 15/09/2018 2 Sub-Saharan Africa (SSA) has a high burden of morbidity and mortality resulting
C 肝職業暴露後之處置 衛福部疾病管制署 中區傳染病防治醫療網 王任賢指揮官
C 肝職業暴露後之處置 衛福部疾病管制署 中區傳染病防治醫療網 王任賢指揮官 HCV:Structure and Classification Unclassified virus, Member of the flavivirus family (other members yellow fever and dengue) Enveloped single stranded RNA virus Humans
Documentation, Codebook, and Frequencies
2 Documentation, Codebook, and Frequencies Laboratory Component: Hepatitis B: core antibody, surface antibody and surface antigen; Hepatitis C: confirmed antibody; Hepatitis D antibody Survey Years: 2003
TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING October2010. Issue Summary
TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING 28-29October2010 Issue Summary Informational Topic: FDA s Geographic Donor Deferral Policy to Reduce the Possible Risk of Transmission
AccuSet HBV Worldwide Performance Panel
PACKAGE INSERT 0805-033 INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot HBV test methods. Characterized samples
Primary Sample Manual Infectious Serology Issue No Effective Date: 20/09/17 Page 1 of 15 EUROFINS BIOMNIS
Issue No. 2.02 Effective Date: 20/09/17 Page 1 of 15 Written / Revised By: Dr. Mike Louw, Medical Director Date: Reviewed By: Date: Dr. Sinead Kelly, Infectious Serology Consultant Authorised By: Jean-Sébastien
Transfusion Risk for Hepatitis B, Hepatitis C and HIV in the State of Santa Catarina, Brazil,
236 BJID 2004; 8 (June) Transfusion Risk for Hepatitis B, Hepatitis C and HIV in the State of Santa Catarina, Brazil, 1991-2001 Emil Kupek Department of Public Health, Federal University of Santa Catarina,
Infectious Disease Diagnostics
Infectious Disease Diagnostics Tackling Infectious Diseases Uppsala Health Summit - October10 th, 2017 Stephan Jäger, Roche Diagnostics GmbH When to tackle infectious diseases Prevention & action contribution
Hepatitis Case Investigation
* indicates required fields Does patient also have: Hepatitis Case Investigation West Virginia Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology
Research Article. Prevalence of Hepatitis B Virus Markers among Blood Donors in Qassim Region, Saudi Arabia
Available online www.ijpras.com International Journal of Pharmaceutical Research & Allied Sciences, 2017, 6(1):99-106 Research Article ISSN : 2277-3657 CODEN(USA) : IJPRPM Prevalence of Hepatitis B Virus